Live tape
Top 8, mentions 7d7,546META2,265 mentions▲ +0.06GOOGL1,512 mentions▲ +0.02NVDA806 mentions▲ +0.09MUSE666 mentions▲ +0.07MSFT606 mentions▲ +0.06SPY573 mentions▲ +0.05QQQ564 mentions▲ +0.08TSLA554 mentions▲ +0.06

Equity · Healthcare

KYMR

Kymera Therapeutics, Inc. · NasdaqGM

$116 +1.75% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Jul 17, 2026
Price · Chart
Our own end-of-day closes 13 sessions
$120.0 $110.0 30 Jun 17 Jul

The line runs $115 on 30 June through $116 on 17 July, on a scale from $110.0 to $120.0. Days the market did not trade hold the previous close, flat.

The chart above plots the price of KYMR over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 13 sessions over that window: $115 on 30 June 2026 through $116 on 17 July 2026.

Market cap $9.6B
52-week range $38 – $119.06
Avg volume 311.6K

Finazon · prior-day close, indicative (IEX-derived, not the official close) · valuation computed from SEC EDGAR filings · as of Jul 17, 2026

KYMR insider trades

SEC Form 4

KYMR has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 29 June 2026.

Date Insider Type Shares Value
29 Jun 2026 Booth Bruce Director Sell 153,300 $16.56M
26 Jun 2026 Booth Bruce Director Sell 467,878 $51.60M
26 Jun 2026 BVF PARTNERS L P/IL Director Sell 1,630,658 $173.67M
25 Jun 2026 Booth Bruce Director Sell 548,321 $65.12M
24 Jun 2026 Booth Bruce Director Sell 134,720 $13.54M
23 Jun 2026 Booth Bruce Director Sell 1,408 $141K
22 Jun 2026 Booth Bruce Director Sell 218,544 $21.52M

KYMR reported financials

SEC EDGAR XBRL

KYMR reported revenue of $39.2M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$311.4M.

Figure Reported Period
Revenue $39.2M 31 Dec 2025 fiscal year
Net income −$311.4M 31 Dec 2025 fiscal year
Diluted EPS −$3.69 31 Dec 2025 fiscal year
Total assets $1.6B 30 Jun 2026 at period end
Total equity $1.5B 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

KYMR earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-0.62 $65M
31 Mar 2026 Q1 2026 $-0.71 $34M
31 Dec 2025 FY 2025 $-3.69 $39M
30 Sep 2025 Q3 2025 $-0.94 $3M
30 Jun 2025 Q2 2025 $-0.95 $11M
31 Mar 2025 Q1 2025 $-0.82 $22M
31 Dec 2024 FY 2024 $-2.98 $47M
30 Sep 2024 Q3 2024 $-0.82 $4M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

KYMR institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a KYMR position for the quarter ended 30 Jun 2026 — a combined $1.1B; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) 8,657,242 $992.7M
Two Sigma Investments Added +44.8% shares 371,374 $42.6M
Marshall Wace New position 167,517 $19.2M
Citadel Advisors Held (±25%) −5.9% shares 111,555 $12.8M
Man Group Added +43.1% shares 19,085 $2.2M
Fisher Asset Management New position 12,732 $1.5M
AQR Capital Management Trimmed −40.2% shares 9,541 $1.1M
D. E. Shaw & Co. New position 2,800 $321K

Source: SEC EDGAR 13F filings

KYMR fails-to-deliver

SEC CNS data

On 25 Aug 2026, 12 shares of KYMR failed to deliver (about $1K).

Settlement date Shares failed Notional % of shares out
25 Aug 2026 12 $1K <0.001%
21 Aug 2026 1,329 $161K 0.002%
19 Aug 2026 2 $243 <0.001%

Source: SEC fails-to-deliver (CNS) data